ArticleHuman genomics2026
A comprehensive analysis of the interaction network of immunomodulatory-related differentially expressed genes, aiming to identify biomarkers associated with Parkinson's disease.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is a multifactorial neurodegenerative disease that results from the interplay of genetic, environmental, and immunological factors. In order to find biomarkers linked to PD, the current study intends to thoroughly explore the interaction network of immunomodulatory-related differentially expressed genes (IMRDEGs).
methodsGeneCards database was used to obtain immunomodulation-related genes (IMRGs), and GEO database was used to obtain the expression profile dataset of GSE224913 and GSE99039 in patients with Parkinson’s disease. Using the limma package, we performed differential analysis to identify differentially expressed genes. Subsequently, we used GO, KEGG and GSEA for enrichment analysis of these differentially expressed genes. In addition, we constructed interaction networks between MRnas and transcription factors (TF), mrnas and drugs, and investigated protein–protein interaction networks (PPIs). Finally, CIBERSORT method was used for immunoinfiltration analysis to estimate the composition and abundance of immune cells.
resultsA total of 6 IMRDEGs were identified in the GSE224913 and GSE99039 datasets. The main focus of enrichment analysis is on immune-related pathways, including dendritic cell development and negative regulation of leucocyte mediated immunity. Most immune cells were associated with 6 IMRDEGs; The associations were highest with neutrophils, static NK cells, and T cells with active CD4 memory. In addition, regulatory networks of mRNA-TF, mRNA-miRNA and mRNA-Drugs target genes were established.
conclusionIn summary, the six core genes (HLA-B, HNRNPA, LILRB1, PARK7, S100A9, and SPI1) play pivotal roles in the progression of PD. The interaction networks encompassing mRNA-TF and mRNA-drugs contribute significantly to our understanding of disease progression and the optimization of treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.